Cancer Tissue Diagnostics Market 2019 Research, Analysis and Forecasted Healthcare Industry with Upcoming Trends and Expectations by 2027

The global cancer tissue diagnostics market is US$ 2,025.41 Mn in 2018 and is predicted to grow at a CAGR of 6.2% during the forecast period 2019 – 2027, to reach US$ 3,419.61 Mn by 2027.

Europe is the second largest geographic market and is expected to be the second most significant revenue contributor in forecast period. The region has witnessed several technological advancements in the field of healthcare by the incorporation of advanced cancer tissue diagnostics in order to increase the efficiency of treatments in the region. The growth is driven by factors such as prevalence of cancer in the countries, increased mortality rates as well as growth strategies adopted by the market players in the European countries.

 Get Sample Report At:-

Cancer is among the leading cause of deaths across the globe and is profoundly affecting the quality of life. Thus, cancer will be a burden on society if not diagnosed and treated on time. According to the World Health Organization in 2018, approximately 9.6 million deaths across the globe were due to cancer. Furthermore, the National Cancer Institute predicted that in 2018, approximately 1,735,350 new cancer cases would be diagnosed in the US.

Additionally, cancer is found to be commonly prevalent in European countries as well. As per the Cancer Research UK, in 2016, around 163,444 deaths in the UK were due to cancer.

Furthermore, Asia Pacific region is also facing the problem of the growing prevalence of cancer. The top 15 countries with Cancer prevalence are Japan, Taiwan, Singapore, South Korea, Malaysia, Thailand, China, Philippines, Sri Lanka, Vietnam, Indonesia, Mongolia, India, Laos, and Cambodia. According to the National Institute of Cancer Prevention and Research (NICPR), in 2018, in India, total deaths due to cancer were 784,821. These statistics determine an increase in the demand for advanced cancer diagnostics in various regions across the globe. Hence, driving the growth of the cancer tissue diagnostics market during the forecast period.

 Leading Cancer Tissue Diagnostics Market Players:

  • Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Bio Rad Laboratories Inc.
  • Abbott
  • Enzo Life Sciences, Inc.
  • Agilent Technologies, Inc.
  • Cancer Genetics Inc.
  • Merck KGaA (Sigma-Aldrich Co. LLC)
  • Abcam plc.

Tissue diagnostics is very crucial in cancer treatment. Cancer tissue diagnostics play a significant role in determining the treatment pace and procedure. Early detection can help in reducing the mortality rates of cancer; hence, medical professionals, market players as well as government authorities implementing new diagnostics and treatment facilities. Thus the rise in investments and better reimbursement policies favor the growth of the cancer tissue diagnostics market.

For instance, in September 2017, OncoStem Diagnostics, invested USD 6 million towards research and development to develop useful tests for brain, colon and oral cancer, and also to automate these tests. Furthermore, Fimmic, which is now, Aiforia Technologies Oy in 2017 invested €5 million to develop, WebMicroscope AI Cloud for tissue diagnostics. Fimmic’s WebMicroscope launched in early 2017, is a tissue diagnostic commercial platform that enables image analysis through deep learning artificial intelligence (AI). In 2019, the company launched AIforia cloud platform, which accelerates image processing and provides automated pathology image analysis. Thus the growing investments for cancer tissue diagnostics have led to the advent of breakthrough techniques, expecting to fuel the growth of the market.

 The target audience for the report on the Cancer Tissue Diagnostics market

  • Manufactures
  • Market analysts
  • Senior executives
  • Business development managers
  • Technologists
  • R&D staff
  • Distributors
  • Investors
  • Governments
  • Equity research firms
  • Consultants

Buy Report At:-

There have been limited developments made in the cancer tissue diagnostics market during recent years. However, growth strategies such as approvals, collaborations, and partnerships have been witnessed in the market of cancer tissue diagnostics. For instance, in June 2019, Agilent Technologies Inc. received the U.S. Food and Drug Administration (FDA) approval for its PD-L1 IHC 22C3 pharmDx assay. The assay is approved to aim in identifying patients with head and neck squamous cell carcinoma (HNSCC) for treatment with KEYTRUDA (pembrolizumab), anti-PD-1 therapy manufactured by Merck. Also, during November 2018, Leica Biosystems, launched the latest PD-L1 antibody for use on their fully automated BOND IHC and ISH staining platform.

About Us:-

The Insight Partners is a one stop industry research provider of actionable intelligence.   We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact us:-

The Insight partners,
Phone: +1-646-491-9876
Email: [email protected]

Posted by on Tuesday September 24 2019, 2:17 AM EDT. All trademarks acknowledged. Filed under Healthcare, Life Sciences. Comments and Trackbacks closed. Follow responses: RSS 2.0

Comments are closed

News Categories

Featured Press Releases

Log in